Forced expression of cytidine deaminase confers sensitivity to capecitabine

Oncology

Volumn 65, Issue 3, 2003, Pages 267-274

  Morita, Tatsuo ^a   Matsuzaki, Atsushi ^a   Kurokawa, Shinsuke ^a   Tokue, Akihiko ^a  

^a JICHI MEDICAL UNIVERSITY   (Japan)

Author keywords

Capecitabine; Cytidine deaminase; Gemcitabine; Sensitivity; Transfection

Indexed keywords

5' DEOXY 5 FLUOROCYTIDINE; CAPECITABINE; COMPLEMENTARY DNA; CYTIDINE DEAMINASE; CYTIDINE DERIVATIVE; DIHYDROPYRIMIDINE DEHYDROGENASE; ENZYME INHIBITOR; FLUOROURACIL; GEMCITABINE; LIPOFECTIN; TETRAHYDROURIDINE; THYMIDINE PHOSPHORYLASE; THYMIDYLATE SYNTHASE; UNCLASSIFIED DRUG;

ARTICLE; BLADDER CARCINOMA; CANCER CELL CULTURE; CONTROLLED STUDY; DRUG EFFECT; DRUG SENSITIVITY; ENZYME ACTIVITY; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; STATISTICAL SIGNIFICANCE;

ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; CELL SURVIVAL; CYTIDINE DEAMINASE; DEOXYCYTIDINE; DIHYDROURACIL DEHYDROGENASE (NADP); DISEASE MODELS, ANIMAL; DNA, COMPLEMENTARY; DRUG SCREENING ASSAYS, ANTITUMOR; ENZYME-LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; THYMIDINE PHOSPHORYLASE; THYMIDYLATE SYNTHASE; TRANSFECTION; TUMOR CELLS, CULTURED; URINARY BLADDER NEOPLASMS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 0344305589     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000074480     Document Type: Article

References (41)

1. Miwa M, Ura M, Nishida M, Sawada N, Ishikawa T, Mori K, Shimma N, Umeda I, Ishitsuka H: Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue. Eur J Cancer 1998;34:1274-1281.
2. Hertel LW, Boder GB Jr, Kroin JS, Rinzel SM, Poore GA, Todd GC, Grindey GB: Evaluation of the antitumor activity of gemcitabine (2′,2′- difluoro-2′-deoxycytidine). Cancer Res 1990;50:4417-4422.
3. Blum JL, Jones SE, Buzdar AU, LoRusso M, Kuter I, Vogel C, Osterwalder B, Burger H-U, Brown CS, Griffin T: Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer. J Clin Oncol 1999;17:485-493.
4. Hoff PM, Ansari R, Batist G, Cox J, Kocha W, Kuperminc M, Maroun J, Walde D, Weaver C, Harrison E, Burger HU, Osterwalder B, Wong AO, Wong R: Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: Results of a randomized phase III study. J Clin Oncol 2001;19:2282-2292.
5. Furukawa T, Yoshimura A, Sumizawa T, Haraguchi M, Akiyama S, Fukui K, Ishizawa M, Yamada Y: Angiogenic factor. Nature 1992;356:668.
6. Ishikawa F, Miyazono K, Hellman U, Drexler H, Wernstedt C, Hagiwara K, Usuki K, Takai F, Risau WW, Heldin C-H: Identification of angiogenic activity and the cloning and the expression of platelet-derived endothelial cell growth factor. Nature 1989;338:557-562.
7. Kaye SB: Gemcitabine: Current status of phase I and II trials. J Clin Oncol 1994;12:1527-1531.
8. Burris HA, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, Cripps MC, Portenoy RK, Storniolo AM, Tarassoff P, Nelson R, Dorr FA: Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomized trial. J Clin Oncol 1997;15:2403-2413.
9. Carmichael J: The role of gemcitabine in the treatment of other tumours. Br J Cancer 1998;78:21-25.
10. Plunkett W, Huang P, Xu YZ, Heinemann V, Grunewald R, Gandhi V: Gemcitabine: Metabolism, mechanisms of action, and self-potentiation. Semin Oncol 1995;22:3-10.
11. Heinemann V, Xu YZ, Chubb S, Sen A, Hertel LW, Grindey GB, Plunkett W: Inhibition of ribonucleotide reduction in CCRF-CEM cells by 2′,2′- difluorodeoxycytidine. Mol Pharmacol 1990;38:567-572.
12. Huang P, Chubb S, Hertel LW, Grindey GB, Plunkett W: Action of 2′,2′-difluorodeoxycytidine on DNA synthesis. Cancer Res 1991;51:6110-6117.
13. Heinemann V, Xu YZ, Chubb S, Sen A, Hertel LW, Grindey GB, Plunkett W: Cellular elimination of 2′,2′-difluorodeoxycytidine 5′-triphosphate: A mechanism of self-potentiation. Cancer Res 1992;52:533-539.
14. Bouffard DY, Laliberte J, Momparler RL: Kinetic studies on 2′,2′-difluorodeoxycytidine (gemcitabine) with purified human deoxycytidine kinase and cytidine deaminase. Biochem Pharmacol 1993;45:1857-1861.
15. Neff T, Blau CA: Forced expression of cytidine deaminase confers resistance to cytosine arabinoside and gemcitabine. Exp Hematol 1996;24:1340-1346.
16. Eda H, Ura M, F-Ouchi K, Tanaka Y, Miwa M, Ishitsuka H: The antiproliferative activity of DMDC is modulated by inhibition of cytidine deaminase. Cancer Res 1998;8:1165-1169.
17. Miwa M, Eda H, Ura M, Ouchi KF, Keith DD, Foley LH, Ishitsuka H: High susceptibility of human cancer xenografts with higher levels of cytidine deaminase to a 2′-deoxycytidine anti-metabolite, 2′-deoxy-2′- methylidenecytidine. Clin Cancer Res 1998;4:493-497.
18. Ishikawa T, Sekiguchi F, Fukase Y, Sawada N, Ishitsuka H: Positive correlation between the efficacy of capecitabine and doxifluridine and the ratio of thymidine phosphorylase to dihydropyrimidine dehydrogenase activities in tumors in human cancer xenografts. Cancer Res 1998;58:685-690.
19. Kirch HC, Schröder J, Hoppe H, Esche H, Seeber S, Schutte J: Recombinant gene products of two natural variants of the human cytidine deaminase gene confer different deamination rates of cytarabine in vitro. Exp Hematol 1998;26:421-425.
20. Lowry OH, Rosenbrough NJ, Farr AL, Randall RJ: Protein measurement with the Folin phenol reagent. J Biol Chem 1951;193:265-275.
21. Schröder JK, Kirch C, Seeber S, Schutte J: Structural and functional analysis of the cytidine deaminase gene in patients with acute myeloid leukaemia. Br J Haematol 1998;103:1096-1103.
22. Schröder JK, Kirch C, Flasshove M, Kalweit H, Seidelmann M, Hilger R, Seeber S, Schutte J: Constitutive overexpression of the cytidine deaminase gene confers resistance to cytosine arabinoside in vitro. Leukemia 1996;10:1919-1924.
23. Lau KM, LaSpina M, Long J, Ho SM: Expression of estrogen receptor (ER)-alpha and ER-beta in normal and malignant prostatic epithelial cells: Regulation by methylation and involvement in growth regulation. Cancer Res 2000;60:3175-3182.
24. Nishida M, Hino A, Mori K, Matsumoto T, Yoshikubo T, Ishitsuka H: Preparation of anti-human thymidine phosphorylase monoclonal antibodies useful for detecting the enzyme levels in tumor tissues. Biol Pharm Bull 1996;19:1407-1411.
25. Mori K, Hasegawa M, Nishida M, Toma H, Fukuda M, Kubota T, Nagasue N, Yamana H, Hirakawa YS, Chung K, Ikeda T, Takasaki K: Expression levels of thymidine phosphorylase and dihydropyrimidine dehydrogenase in various human tumor tissues. Int J Oncol 2000;17:33-38.
26. Spears CP, Shahinian AH, Moran RG, Heidelberger C, Corbett TH: In vivo kinetics of thymidylate synthetase inhibition of 5-fluorouracil-sensitive and -resistant murine colon adenocarcinomas. Cancer Res 1982;42:450-456.
27. Shirasaka T, Nakano K, Takechi T, Satake H, Uchida J, Fujioka A, Saito H, Okabe H, Oyama K, Takeda S, Unemi N, Fukushima M: Antitumor activity of 1 M tegafur-0.4 M 5-chloro-2,4-dihydroxypyridine-1 M potassium oxonate (S-1) against human colon carcinoma orthotopically implanted into nude rats. Cancer Res 1996;56:2602-2606.
28. Marunaka T, Umeno Y, Yoshida K, Nagamachi M, Minami Y, Fujii S: High-pressure liquid chromatographic determination of ftorafur [1-(tetrahydro-2-furanyl)-5-fluorouracil] and GLC-mass spectrometric determination of 5-fluorouracil and uracil in biological materials after oral administration of uracil plus ftorafur. J Pharm Sci 1980;69:1296-1300.
29. 3H-thymidine incorporation assay. J Immunol Methods 1994;170:211-224.
30. Morita T, Tokue A: Biomodulation of 5-fluorouracil by interferon α in human renal carcinoma cells: Relation to the expression of thymidine phosphorylase. Cancer Chem Pharm 1999;44:91-96.
31. Veerman G, Ruiz van Haperen VW, Vermorken JB, Noordhuis P, Braakhuis BJ, Pinedo HM, Peters GJ: Antitumor activity of prolonged as compared with bolus administration of 2′,2′-difluorodeoxycytidine in vivo against murine colon tumors. Cancer Chemother Pharmacol 1996;38:335-342.
32. Ishikawa T, Sekiguchi F, Fukase Y, Sawada N, Ishitsuka H: Positive correlation between the efficacy of capecitabine and doxifluridine and the ratio of thymidine phosphorylase to dihydropyrimidine dehydrogenase activities in tumors in human cancer xenografts. Cancer Res 1998;58:685-690.
33. Reigner B, Verweij J, Dirix L, Cassidy J, Twelves C, Allman D, Weidekamm E, Roos B, Banken L, Utoh M, Osterwalder B: Effect of food on the pharmacokinetics of capecitabine and its metabolites following oral administration in cancer patients. Clin Cancer Res 1998; 4:941-948.
34. Budman DR, Meropol NJ, Reigner B, Creaven PJ, Lichtman SM, Berghorn E, Behr J, Gordon RJ, Osterwalder B, Griffin T: Preliminary studies of a novel oral fluoropyrimidine carbamate: Capecitabine. J Clin Oncol 1998;16:1795-1802.
35. Morita T, Matsuzaki A, Suzuki K, Tokue A: Role of thymidine phosphorylase in biomodulation of fluoropyrimidines. Curr Pharm Biotechnol 2001;2:257-267.
36. Morita T, Matsuzaki A, Tokue A: Enhancement of sensitivity to capecitabine in human renal carcinoma cells transfected with thymidine phosphorylase cDNA. Int J Cancer 2001;92:451-456.
37. Hidalgo M, Castellano D, Paz-Ares L, Gravalos C, Diaz-Puente M, Hitt R, Alonso S, Cortes-Funes H: Phase I-II study of gemcitabine and fluorouracil as a continuous infusion in patients with pancreatic cancer. J Clin Oncol 1999;17:585-592.
38. Rini BI, Vogelzang NJ, Dumas MC, Wade JL 3rd, Taber DA, Stadler WM: Phase II trial of weekly intravenous gemcitabine with continuous infusion fluorouracil in patients with metastatic renal cell cancer. J Clin Oncol 2000;18:2419-2426.
39. Mani S, Vogelzang NJ, Bertucci D, Stadler WM, Schilsky RL, Ratain MJ: Phase I study to evaluate multiple regimens of intravenous 5-fluorouracil administered in combination with weekly gemcitabine in patients with advanced solid tumors: A potential broadly active regimen for advanced solid tumor malignancies. Cancer 2001;92:1567-1576.
40. Herrmann R, Borner M, Morant RAD, Roth AD, Ludwig C, Bedoucha V: Combining gemcitabine (GEM) and capecitabine (CAP) in advanced pancreatic cancer. Proc Am Soc Clin Oncol 2000;19:267a.
41. Schilsky RL, Bertucci D, Vogelzang NJ, Kindler HL, Ratain MJ: Dose-escalating study of capecitabine plus gemcitabine combination therapy in patients with advanced cancer. J Clin Oncol 2002;20:582-587.